Sustainability reports and resources

Home / Sustainability / Sustainability reports and resources

Our commitments and progress across our priority environmental, social and governance (ESG) goals and supporting documents.

Find our latest Sustainability Report and supporting documents to learn more about our sustainability priorities and CSR strategy. This include our Taskforce for Climate-related Financial Disclosures (TCFD) reports, ESG position statements and polices, materiality assessment results and letters of assurance from third parties.

Sustainability Report

Our annual Sustainability Report describes our approach and progress based on sustainability focus area, with Data Annex for performance measures and targets. 

Annual sustainability reporting





Policies and standards

Our Global ABAC Standard supports our commitment to operate ethically, specifically explaining how to be people of integrity in all of our dealings with third parties of any kind.

This policy defines the principles, behaviours and ethical standards behind our global R&D efforts. It covers topics such as: clinical trials, patient safety, privacy of information, genomic information, GMOs, animals in research, Nagoya protocol, etc.

We want AstraZeneca to be a great place to work where everyone feels respected, supported and safe. This documents sets out our principles and the we responsibilities to ensure our work environment is inclusive, to free our diverse & uniquely talented employees to drive innovation and perform our best.

Our Code of Ethics is the foundation for our sustainability strategy. It defines our values at work and guides everything we do, ensuring that we deliver life-changing medicines in a responsible way.

Sets out requirements for processing personal data and aligns with and, in some cases, exceeds the requirements of applicable laws and regulations. We value the personal data entrusted to us, and we are committed to collecting, using, retaining, and disclosing personal data in a fair, transparent and secure way.

We recognise that there are circumstances where patients with serious or life-threatening diseases have exhausted all available therapeutic options and may not be eligible to enrol in one of our clinical trials. In such circumstances individual patients may be eligible for early access to an AstraZeneca investigational medicinal product.

This document provides the minimum standards for the identification and assessment of ergonomic hazards and other human factors. Ergometry refers designing workplaces for employees' physiological and psychological needs.

This handbook summarises what AstraZeneca believes is required to do the right thing and what we expect of all Third Parties that work with us, for us, or on our behalf. These expectations are part of our fundamental commitment to work only with others who embrace ethical standards consistent with ours.

When we promote our products, we provide accurate information based on scientific evidence.

We follow Good Publications Practice guidelines and ICMJE Recommendations in sharing objective, meaningful scientific information about our studies without compromising our intellectual property.


Our Global Safety, Health and Environment (SHE) Standard describes our commitment to, management of, and accountability for SHE. We are committed to providing a work environment that is both physically and psychologically safe for everyone.

These Global Standards set out our expectations for behaviour to ensure everyone feels respected, supported and safe at work from any form of bullying and harassment, be it mental, physical or sexual.

This guide builds on our compliance expectations to describe our vision for supply chain sustainability. It also provides a common way to assess and reward performance by our sourcing teams.

This document outlines workplace noise and vibration hazards, with the objective of protecting people from health effects associated with poor management of these issues.

Statements and publications

This document outlines our approach to making our medicines available and affordable, and how we work together with healthcare systems to support sustainable access to healthcare.

This Statement introduces our science-based approach to biodiversity. We are developing a deeper understanding of our relationship with nature, and we are committed to supporting global progress towards the goals outlined in the Kunming-Montreal global biodiversity framework.

This document details our approach to monitoring conflict minerals that may be used to manufacture our products.

This paper explores the interconnection between climate and health, and the need to decarbonise health systems while improving resilience.

In our Gender Pay Gap Reports, we provide gender pay information for AstraZeneca in the United Kingdom and outline our plans for supporting women, as well as continuing to improve the diversity of our company globally.

This statement details how AstraZeneca respects the rights of all stakeholders - including employees, patients, suppliers, communities, and the environment. We are committed to treating everyone with dignity and respect and to ensuring that third parties we work with do the same.

This statement describes our commitment to expand access to healthcare through intellectual property (IP). AstraZeneca sees IP as a driver for innovation that will lead to the discovery of new medicines.

AstraZeneca is committed to operating with integrity and high ethical standards. This includes ensuring that our business respects human rights - a commitment reflected in our Code of Ethics, which is based on our Company Values and includes our global “Our Interactions” Policy. Specifically, we are committed to ensuring that we identify and eliminate to the fullest extent practicable modern-day slavery or human trafficking in our business.

This document intends to make our tax approach transparent by detailing our governance, risk management, compliance, tax planning, dealings with tax authorities, etc.

As a responsible healthcare company, we make it a priority to effectively manage the risks associated with pharmaceuticals in the environment (PIE).

This document outlines how our research and development activities and resource allocation are included in our efforts to embed equitable access practices into our product portfolio.

Our Water Stewardship Position Paper sets out our approach to minimising our impact on water and making a positive contribution to water stewardship in the river basins where we operate.

Code of Ethics

Our Code of Ethics defines our values at work and guides everything we do, ensuring that we deliver life-changing medicines in a responsible way.